View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 19, 2021updated 12 Jul 2022 11:13am

Elligo Health and Laguna Clinical partner to boost trials access

Elligo Health Research and Laguna Clinical Research Associates partner to expand access to clinical trials.

Elligo Health Research has partnered with Laguna Clinical Research Associates (LCRA) to expand access to clinical trials in diverse communities.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The partners will collaborate with more than 20 urgent care locations in these communities. Laguna will deliver medical services and clinical research as a care option to varied patient populations via Elligo.

Elligo and Laguna aim to connect clinical experts with research infrastructure to offer a clinical trial execution solution that will enable better patient access and engagement.

The new model will work with healthcare providers and patients to increase resources and provide direct access to eSource data from clinical sites.

Laguna Clinical Research Associates CEO Dr Veronica Procasky said: “Partnering with Elligo allows us to build on our successful model for implementing urgent care and clinical research, which pairs the rapid implementation of clinical trials with the utmost care and safety of our patients.”

In 2019, Elligo Health raised $20m in a Series C funding round to further boost physician and patient access to clinical trials using its Goes Direct approach and IntElligo Research Stack clinical technology.

Elligo Health Research CEO John Potthoff said: “Partnering with LCRA will allow Elligo to bring access for clinical research to additional ethnically diverse patients.

“Bringing more research as a care option to patients by expanding to even more diverse populations offers significant benefits for current patients and the future of cutting-edge medical treatments.”

In a separate development, connected healthcare solutions provider VivaLNK reported results from a survey, which found that 44% of all clinical research will deploy decentralised clinical trials within the coming 12 months.

The survey involved pharmaceutical, biotechnology and clinical research professionals, who provided their opinions on the current use of remote patient monitoring (RPM).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena